Corporate Fact Sheet

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies, which have applicability across broad therapeutic domains.

Company Highlights

- Emerging leader in developing cutting-edge, immuno-oncology therapeutics
- Pipeline comprising seven differentiated immuno-oncology clinical candidates
- Leading multispecific antibody platforms, with multiple DART® molecules in clinic
- Fully-integrated mAb-based development capabilities, including GMP manufacturing
- Collaborations with Roche, Incyte, Servier, Pfizer and Boehringer Ingelheim
- Experienced management team and highly collaborative corporate culture

Immuno-Oncology Pipeline

<table>
<thead>
<tr>
<th>Program (Target)</th>
<th>Indication</th>
<th>Pre-IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Collaborator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margetuximab (HER2)</td>
<td>Breast (HER2+) “SOPHIA”</td>
<td>Gastric (+anti-PD-1)</td>
<td>Green Cross</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flotetuzumab (CD123 x CD3)</td>
<td>AML</td>
<td>AML (+MGA012)</td>
<td>Planned</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGA012 (PD-1)</td>
<td>Solid Tumors</td>
<td>Incyte®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD013 (PD-1 x LAG-3)</td>
<td>Solid Tumors/Heme Mal.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD019 (PD-1 x CTLA-4)</td>
<td>Solid Tumors</td>
<td>2018 IND</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enoblituzumab (B7-H3)</td>
<td>Solid Tumors (+ anti-PD-1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD009 (B7-H3 x CD3)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD019 (B7-H3 x CD3)</td>
<td>Solid Tumors (+MGA012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGC018 (B7-H3)</td>
<td>Solid Tumors</td>
<td>2018 IND</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD007 (gpA33 x CD3)</td>
<td>Colorectal (+MGA012)</td>
<td>Planned</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a) MGC018 is an antibody-drug conjugate (ADC) based on a duocarmycin payload with cleavable peptide linker that was licensed from Synthon Biopharmaceuticals.
(b) MacroGenics retains rights to develop its pipeline assets in combination with MGA012 and to manufacture a portion of global clinical and commercial supply needs of MGA012.

MacroGenics’ Antibody Formats

DART and TRIDENT™ therapeutics enable the targeting of multiple antigens or cells with a single antibody-like molecule. Applications include the recruitment of a patient’s T cells to destroy targeted cancer cells and the engagement of two checkpoint inhibitors for improved activation of the immune system. The flexibility of this platform allows for the design of molecules with extended half-life and increased valency.

Fc-Optimized antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy tumor cells.

Quick Facts

Employees: 353 (as of 5/16/18)

Cash & Investments: $363M at 3/31/18 (Pro Forma)

Shares Outstanding: 42.2M at 3/31/18 (Pro Forma)

Ticker: MGNX (NASDAQ)

Locations: Rockville, MD
Brisbane, CA

Platforms:
DART (bisppecific)
TRIDENT (trispecific)
Fc Optimization

Key Collaborations

MacroGenics has developed significant alliances with leading pharmaceutical and biotechnology companies. Collaboration partners that have provided significant non-dilutive funding include:

Roche
Incyte
Servier
Boehringer Ingelheim
Pfizer

© 2018 MacroGenics, Inc. All rights reserved.
The information in this fact sheet is current as of May 15, 2018, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with the SEC.
MacroGenics undertakes no obligation to update any of the information herein.
MacroGenics’ Lead Product Candidates

**Margetuximab (HER2)**  
*Fc-optimized mAb*  
**Phase 3**

Margetuximab is an Fc-optimized mAb that targets HER2-expressing tumors, including breast and gastroesophageal cancers. MacroGenics has engineered the Fc region of margetuximab to enhance its Fc-mediated effects, including improved ADCC. MacroGenics is conducting a Phase 3 registration trial (SOPHIA) in mBC patients to demonstrate clinical superiority to trastuzumab. The company is also enrolling a Phase 2 study for the treatment of advanced gastric cancer in combination with anti-PD-1, and presented encouraging data for this study at 2018 ASCO GI.

**Flotetuzumab (CD123 x CD3)**  
*Bispecific DART molecule*  
**Phase 1**

Flotetuzumab is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is over-expressed on cancer cells in a wide range of hematological malignancies, including acute myeloid leukemia (AML). An ongoing Phase 1, first-in-human study of flotetuzumab is being conducted to determine safety, tolerability, maximum tolerated dose and anti-leukemic activity in patients with relapsed or refractory AML.

**MGD013 (PD-1 x LAG-3)**  
*Bispecific DART molecule*  
**Phase 1**

Monoclonal antibodies that target the immune checkpoints LAG-3 and PD-1 have shown enhanced clinical antitumor activity when given in combination. Recognizing the therapeutic potential of dual checkpoint blockade, we have engineered MGD013, a bispecific DART molecule, to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. MGD013 has demonstrated a favorable preclinical safety and toxicological profile and is currently being evaluated in a Phase 1 dose escalation study.

**B7-H3 Franchise**  
*Multiple molecules*

MacroGenics is developing a portfolio of first-in-class therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation and believed to inhibit T-cell activation. B7-H3 overexpression has been correlated with disease severity and poor outcome in several cancer types.

- **Enoblituzumab** is an Fc-optimized mAb that targets B7-H3 to take advantage of this antigen’s broad expression across solid tumors. The company has completed enrollment of a combination study with an anti-PD-1 molecule and expects to report this data in 2H18.
- **MGD009** is a DART molecule that targets B7-H3 and CD3 and was designed to redirect T cells, via their CD3 component, to kill B7-H3-expressing cancer cells. A Phase 1 dose-escalation study of MGD009 is ongoing.
- **MGC018** is an antibody drug conjugate (ADC) comprised of a humanized B7-H3 mAb conjugated to a potent DNA-alkylating payload via a cleavable peptide linker. We anticipate submitting the IND application for MGC018 in 2018.